Malaria in the Post-Partum Period; a Prospective Cohort Study

Machteld E. Boel1,2*, Marcus J. Rijken1, Tjalling Leenstra2, Aung Pyae Phyo1, Mupawjay Pimanpanarak1, Naw Lily Keereecharoen1, Stephane Proux1, Natthapon Laochan1, Mallika Imwong3, Pratap Singhayasivanon3, Nicholas J. White3,4, Rose McGready1,3,4, François H. Nosten1,3,4
1 Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand, 2 Center for Tropical Medicine and Travel Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, 3 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, 4 Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

Abstract

Background: Several studies have shown a prolonged or increased susceptibility to malaria in the post-partum period. A matched cohort study was conducted to evaluate prospectively the susceptibility to malaria of post-partum women in an area where P.falciparum and P.vivax are prevalent.

Methods: In an area of low seasonal malaria transmission on the Thai-Myanmar border pregnant women attending antenatal clinics were matched to a non-pregnant, non-post-partum control and followed up prospectively until 12 weeks after delivery.

Results: Post-partum women (n = 744) experienced significantly less P.falciparum episodes than controls (hazard ratio (HR) 0.39 (95%CI 0.21–0.72) p = 0.003) but significantly more P.vivax (HR 1.34 (1.05–1.72) p = 0.018). The reduced risk of falciparum malaria was accounted for by reduced exposure, whereas a history of P.vivax infection during pregnancy was a strong risk factor for P.vivax in post-partum women (HR 13.98 (9.13–21.41), p<0.001). After controlling for effect modification by history of P.vivax, post-partum women were not more susceptible to P.falciparum than controls (HR: 0.33 (0.21–0.51), p<0.001). Genotyping of pre-and post-partum infections (n=10) showed that each post-partum P.falciparum was a newly acquired infection.

Conclusions: In this area of low seasonal malaria transmission post-partum women were less likely to develop falciparum malaria but more likely to develop vivax malaria than controls. This was explained by reduced risk of exposure and increased risk of relapse, respectively. There was no evidence for altered susceptibility to malaria in the post-partum period. The treatment of vivax malaria during and immediately after pregnancy needs to be improved.

Introduction

For nearly a century it has been known that pregnant women are more susceptible to malaria than non-pregnant women of a similar age[1]. Less is known about susceptibility in the post-partum period. Some studies report prolonged and increased susceptibility to malaria comparable to that in pregnancy[2,3], while others report spontaneous clearance of P.falciparum parasites within 24 hours of delivery[4,5]. A recent review including 11 studies suggests a transition phase after delivery in which the susceptibility gradually returns to pre-pregnancy levels[6]. P.falciparum genotyping suggested persistence of parasites acquired during pregnancy into the post-partum period[3,7]. Submicroscopic infections and ineffective malaria treatment during pregnancy increase the risk of recrudescence in the post-partum period[6,7]. In contrast there are no reports on P.vivax in the post-partum period.

We conducted a matched cohort study to determine prospectively whether post-partum women are at increased risk of P.falciparum and P.vivax malaria in the 12 weeks following delivery.

Materials and Methods

Ethics statement

Ethics approval was obtained from the ethics committee at the Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand (MUTM 2007-023) and at Oxford Tropical Medicine Ethical Committee, Oxford University, England (Code 002-07) and yearly renewed. All participants gave written, informed, or thumb print if illiterate, consent before enrolment in the study.
Study population and Antenatal care

The Shoklo Malaria Research Unit (SMRU) antenatal clinics (ANC) are located on the north western border of Thailand where there is low seasonal transmission of both multidrug resistant \textit{P.falciparum} and increasingly resistant \textit{P.vivax} malaria[8]. There is currently no safe and effective drug for chemophrophylaxis or intermittent preventive treatment (IPT) in pregnancy. Early detection and treatment of malaria with an artemisinine-based combination therapy (ACT) has been deployed in the area since 1994[9,10]. For pregnant women active weekly detection and early treatment is the only method to prevent maternal death from malaria[8]. Anemia prophylaxis or treatment is provided to all women. All confirmed episodes of malaria are treated according to international guidelines[11,12]: \textit{P.falciparum} is treated with mefloquine + artesunate in non-pregnant individuals, and with quinine (first trimester) or artesunate + clindamycin in pregnant individuals. \textit{P.vivax} is treated with chloroquine. Primaquine is not used in the study population, because it is contraindicated during pregnancy and lactation. Also in the non-study population primaquine is not widely used, because of high rates of G6PD deficiency. The prevalence of HIV and syphilis is less than 0.5% in this population[13].

The majority of women presented in this study are migrant workers from Myanmar, who don’t have easy access to the Thai health system. Therefore it is unlikely that women with fever would present at other clinics than at SMRU clinics, where medical care is free of charge.

Procedures

All women attending the ANC from November 2007 to September 2009 were asked to participate. At inclusion a socio-economic questionnaire was conducted and malaria history documented. Before delivery each woman was asked to help find a female friend or relative of similar age (+/- 10 years), living within 200 meters, who was not pregnant or recently delivered who would be a control for the 12 weeks post-partum period. Pregnancy in the control women was excluded by urine \textbeta-HCG test (Bioline HCG strip) at enrolment and again at week 12. Weekly smears, blood spots on Whatman 3 M filter paper and symptom questionnaires on residential location, insecticide treated bed nets (ITN) usage and self treatment with antimalarial drugs and monthly hematocrit were obtained from both groups for 12 weeks.

Blood smears (thin and thick films) were stained with Giemsa and read directly on site for 200 fields before being declared negative. Quality control by experienced technicians revealed a negative predictive value of the routine lab technicians of 97.1% (232/239), and a positive predictive value 97.7% (338/346). Blood spots on filter paper were dried and stored for later analysis.

Genotyping

Pregnancy and delivery blood samples of women who were malaria negative by microscopy during pregnancy, but had malaria in the post-partum period were screened for submicroscopic infection. For parasite detection the genes encoding the small subunit ribosomal RNA (ssRNA) were amplified, then species-specific primer-pairs were used in the nested round[14]. For \textit{P. falciparum} pre-and post-partum 3-locus genotypes (MSP-1, MSP-2 and GLURP) were compared[15,16]. Sub-microscopic infections were not counted as malaria infections in the incidence and risk calculations, and not treated, because analysis was performed later.

Sample size calculation

A sample size of 713 post-partum women and 713 controls was required to allow the detection of an increase in the cumulative proportion of women with malaria during the 12 weeks from 5% in the control women to 10% in the women post-partum with 90% power, 95% confidence, and 15% drop out.

Statistical analysis

Data were analysed in SPSS for Windows version 18.0, STATA version 11 and R version 2.12. Baseline comparisons were made using Student’s t-test and Mann–Whitney U-test. Proportions were compared using the Chi-square test. For incidence-rates and time-to-event analysis the time to the first microscopically confirmed \textit{P.vivax} or \textit{P.falciparum} infection in the 12 week period was calculated, after which the woman was censored. If a \textit{P.falciparum} infection preceded a \textit{P.vivax} infection, three weeks were subtracted from the weeks for \textit{P.vivax} incidence-rate, because the antimalarial treatment of \textit{P.falciparum} prevents \textit{P.vivax}. If a \textit{P.vivax} infection preceded a \textit{P.falciparum} infection, the \textit{P.falciparum} incidence-rate was unchanged, because chloroquine is ineffective against \textit{P.falciparum} in this area[17]. Mixed infections (\textit{P.vivax} and \textit{P.falciparum} infection at the same time) were counted in both incidence-rates. The incidence of malaria in post-partum women was compared to the incidence in controls using Cox-proportional hazards regression with shared frailty[10] to adjust for the non-independence of observations resulting from pair-matching. Though matching was expected to preclude confounding, residual confounding by factors not used for matching was evaluated by assessing the change in the main effect following inclusion of these factors in the Cox-regression model. The time to the first symptomatic non-malaria febrile episode was compared between post-partum and control women using above Cox-regression methods separately for the first and the last 6 weeks. A linear mixed regression model was used to model mean change in hematocrit during follow-up. A model including random intercepts and slopes for individuals best fitted the data. The functional form of mean change in hematocrit over time was explored and was best fit as a linear spline with a single knot at 4 weeks.

If a woman was absent from planned follow-up she was considered to be malaria and fever negative, assuming that most people become symptomatic when infected with malaria in this area,[19] and present to medical attention. Women were considered as lost to follow-up if follow-up was discontinued and the woman did not return within the study period. From women who became pregnant during the post-partum study, the date of conception was back-calculated by use of ultrasound and only data collected before the date of conception was used for analysis.

Results

From November 2007 until September 2009, 824 women were enrolled during pregnancy, of whom 744 started the post-partum follow-up. Of these 744 women, 722 (97%) had a matched control (Fig. 1). The groups were comparable except that as expected post-partum women had a slightly higher median number of previous pregnancies, and more often reported a history of malaria in the previous 9 months (Table 1). Over 90% of women reported sleeping under an ITN.

Women in the control group were more likely to work away from home, in the field or forest (Table 2). A higher proportion of post-partum women (>90%) completed follow-up compared to controls (>80%). Few women reported self-treatment of fever with antimalarials; 6/1466 (0.4%): in two malaria parasites were detected, the other 4 women remained malaria negative. Two
post-partum women died during the study period. One died at home 11 days after delivery from dysentery. The other woman died 24 days after delivery from severe malaria in a hospital in Myanmar.

Malaria

The proportion of post-partum women with any malaria in the 12 week follow up period was 168/744 (22.6%) compared to 138/722 (19.2%).

Table 1. Characteristics of post-partum women and controls.

| Characteristics                    | Post-partum (n = 744) | Controls (n = 722) | P-value |
|------------------------------------|----------------------|--------------------|---------|
| Age (years), median (iqr)          | 27 (23–33), [18–48]  | 27 (22–33), [18–51]| NS      |
| <21 years                          | 145 (19.5)           | 130 (18.0)         | NS      |
| Parity (P), median (iqr)           | 3 (1–4), [1–14]      | 2 (1–3), [0–13]   | <0.001  |
| Nullipara                          | 0                    | 172 (23.8)         | <0.001  |
| Primipara (P = 1)                  | 196 (26.4)           | 131 (18.1)         | <0.001  |
| Multipara (P > 1)                  | 548 (73.6)           | 419 (58.0)         | <0.001  |
| Years of schooling, median (iqr)   | 3 ± 3                | 3 ± 3              | NS      |
| Literate                           | 448 (60.3)           | 472 (65.4)         | 0.046   |
| Smoke                              | 177 (23.7)           | 172 (23.7)         | NS      |
| Use of bed nets                    | 678 (91.1)           | 673 (93.2)         | NS      |
| Distance to the clinic, median (iqr)| 38 ± 29            | 38 ± 27            | NS      |
| Socio-economic status:             |                      |                    |         |
| Lower group                        | 193 (25.9)           | 213 (29.6)         | NS      |
| Middle group                       | 366 (49.2)           | 350 (48.5)         | NS      |
| Upper group                        | 185 (24.9)           | 159 (22.0)         | NS      |
| History of *P.falciparum*          | 117 (15.7)           | 22 (3.0)           | <0.001  |
| History of *P.vivax*               | 244 (32.8)           | 25 (3.5)           | <0.001  |

Data presented as mean ± standard deviation, median (inter quartile range), [min-max] or n (%). NS; not significant doi:10.1371/journal.pone.0057890.t001
711 (19.4%) of the controls, p = 0.140. The incidence of P.falciparum malaria was lower in the post-partum women compared to control women, but the reverse was true for P.vivax episodes (Table 3). The crude hazard ratio (HR) in post-partum women compared to controls for P.falciparum and P.vivax was 0.39 (0.21–0.72) p = 0.003 and 1.54 (1.05–1.72) p = 0.018, respectively (Table 4). Occupational exposure and a history of P.falciparum in the previous 9 months were both associated with an increased risk of P.falciparum malaria (p<0.001 for both, Table 4). After adjusting for exposure (use of an ITN, sleeping or working outside in the field/forest) the hazard ratio for P.falciparum was attenuated and no longer significant (p = 0.260, Table 5).

Table 2. Observations during study follow-up in post-partum mothers and controls.

|                        | Post-partum (n = 744) | Controls (n = 722) | P-value |
|------------------------|-----------------------|-------------------|---------|
| Follow-up completed    | 694 (93.3)            | 604 (83.7)        | <0.001  |
| No absence during 12 weeks | 349 (46.9)       | 180 (24.9)        | <0.001  |
| Absent 1 or 2 times    | 280 (37.6)            | 274 (38.0)        | NS      |
| Absent >6 times         | 26 (3.5)              | 53 (7.3)          | <0.001  |
| Slept without a bed net at least 1 night during follow-up | 66 (8.9)           | 49 (6.9)          | NS      |
| Slept at least 1 day in the field/forest during follow-up | 83 (11.2)         | 96 (13.3)         | NS      |
| Worked at least 1 day in the field/forest during follow-up | 83 (11.2)         | 282 (39.1)        | <0.001  |
| Became pregnant during follow-up | 4 (0.5)          | 28 (3.9)          | <0.001  |
| Reported self treatment with antimalarials | 2 (0.3)           | 4 (0.6)           | NS      |

Data presented as n (%). NS; not significant
doi:10.1371/journal.pone.0057890.t002

Malaria in the Post-Partum Period

Table 3. Incidence-rates of P.vivax and P.falciparum during the 12 weeks post-partum follow-up.

|                       | No. of woman-weeks of follow up | No. of first episodes within 12 weeks | Incidence-rate of first episodes per 1000 woman-weeks (95% CI) | P-value |
|-----------------------|---------------------------------|--------------------------------------|---------------------------------------------------------------|---------|
| P.falciparum          | Post-partum mothers             | 8538                                 | 23                                                            | 2.7 (1.75–3.98) | 0.022  |
| Controls              | 7609                            |                                      | 36                                                            | 4.7 (3.36–6.48) |         |
| P.vivax               | Post-partum mothers             | 7662                                 | 155                                                           | 20.2 (17.2–23.6) | 0.016  |
| Controls              | 7160                            |                                      | 110                                                           | 15.4 (12.7–18.4) |         |

doi:10.1371/journal.pone.0057890.t003

PLOS ONE | www.plosone.org
March 2013 | Volume 8 | Issue 3 | e57890
Discussion

p = 0.048. Post-partum women with P.vivax malaria during follow-up had a 0.62% (0.14–1.27) lower rate of hematocrit increase per week following malaria, compared to post-partum women without P.vivax.

Table 4. Hazard ratios for different factors for P.falciparum and P.vivax during the 12 weeks post-partum follow-up.

| Factor                             | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value |
|------------------------------------|-----------------------|---------|-----------------------|---------|
| Being a post-partum woman          | 0.39 (0.21–0.72)      | 0.003   | 1.34 (1.05–1.72)      | 0.018   |
| Multipara                          | 0.33 (0.16–0.67)      | 0.005   | 1.11 (0.85–1.45)      | 0.44    |
| ≤21 years                          | 1.28 (0.67–2.43)      | 0.46    | 1.38 (1.02–1.39)      | 0.036   |
| Smoke                              | 1.06 (0.57–1.96)      | 0.86    | 1.35 (1.02–1.80)      | 0.038   |
| Illiterate                         | 0.61 (0.27–1.42)      | 0.26    | 1.23 (0.95–1.60)      | 0.11    |
| Not used the bednet some nights    | 0.94 (0.33–2.70)      | 0.91    | 0.84 (0.51–1.42)      | 0.53    |
| Slept outside some nights          | 1.83 (0.91–3.69)      | 0.09    | 1.30 (0.89–1.89)      | 0.17    |
| Worked in the field/forest         | 2.41 (1.40–4.15)      | 0.002   | 1.10 (0.82–1.46)      | 0.52    |
| History of P.falciparum            | 3.86 (2.12–7.05)      | <0.001  | 3.12 (2.27–4.27)      | <0.001  |
| History of P.vivax                 | 2.12 (1.21–3.71)      | 0.009   | 6.58 (5.14–8.43)      | <0.001  |
| History of P.vivax recurrences     | 0.67 (0.27–1.63)      | 0.374   | 2.53 (1.66–3.87)      | <0.001  |
| History of any malaria             | 2.17 (1.26–3.73)      | 0.005   | 5.64 (4.39–7.24)      | <0.001  |

doi:10.1371/journal.pone.0057890.t004

Table 5. Adjusted hazard ratios for the effect of being a post-partum woman on P.falciparum and P.vivax.

| Factor                             | Hazard ratio (95% CI) for P.falciparum | P-value | Hazard ratio (95% CI) for P.vivax | P-value |
|------------------------------------|---------------------------------------|---------|-----------------------------------|---------|
| Crude risk being a post-partum woman | 0.39 (0.21–0.72)                     | 0.003   | 1.34 (1.05–1.72)                  | 0.018   |
| Adjusted for age, parity, illiteracy, smoke | 0.58 (0.34–1.00)                     | 0.050   | 1.36 (1.06–1.75)                  | 0.017   |
| Adjusted for exposure (occupation, sleeping outside, bed net use) | 0.72 (0.40–1.27)                     | 0.260   | 1.47 (1.13–1.92)                  | 0.004   |
| Adjusted for history of P.falciparum | 0.36 (0.20–0.65)                     | <0.001  | na                                | na      |
| Adjusted for history of P.vivax     | na                                    | na      | 0.47 (0.34–0.64)                  | <0.001  |

na: not applicable.

doi:10.1371/journal.pone.0057890.t005
not suggest any alteration in clinical features. There are several possible explanations for the divergent conclusions: firstly the study in Senegal took place in an area of resistance to deployed drugs and high levels of sub-patent *P. falciparum* were reported[25,26,27], and women with asymptomatic low parasitemia were not treated during pregnancy making it likely that the women carried the parasites into the post-partum period. Secondly there is the issue of misdiagnosis. We found post-partum women to have more febrile episodes (irrespective of malaria) in the first month after delivery than controls. When clinical malaria is an endpoint (as in the study in Senegal) in an area of intense transmission, women after delivery may be more likely to have fevers and coincidental parasitemia. This is supported by the finding in the study in Senegal that there was no increased incidence in asymptomatic *P. falciparum* infections after delivery.

In post-partum women as well as in controls the usage of ITNs was high. The few women who reported that they had not been sleeping under their ITN did not have an increased risk of getting malaria. Although the numbers were small, this is consistent with previously reported data in this area that did not show a significantly protective effect on parasitaemia of ITNs in pregnancy, possibly due to the main vectors for malaria in this area which prefer to bite at sunset and sunrise, when adults are not sleeping under their bed net[28].

There are several limitations of this study: The history of malaria in the previous 9 months in the post-partum women was obtained from the pregnancy records with weekly screening results reported, whilst the history of control women was obtained more from the pregnancy records with weekly screening results. Malaria in the previous 9 months in the post-partum women was sleeping under their bed net[28].

There are several limitations of this study: The history of malaria in the previous 9 months in the post-partum women was obtained from the pregnancy records with weekly screening results reported, whilst the history of control women was obtained more passively, from the patients handheld medical record if available, or from the patients recall possibly resulting in under-reporting. Another limitation was that the heterogeneity of transmission in the study area was not assessed, but the matching of control women on residency within 200 meters of the pregnant woman should have controlled for this.

In conclusion, in this area where *P. falciparum* infection during pregnancy is detected and treated early and aggressively and submicroscopic infection is rare, post-partum women are less susceptible for *P. falciparum* than controls, but this is explained by lower exposure. For *P. vivax* the treatment during pregnancy is limited to the blood stage infection because primaquine is contraindicated in pregnancy. Relapse rates are high and commonly present in the post-partum period. Treatment for the *P. vivax* hypnozoites with primaquine after delivery would be beneficial, but safety for the breastfeeding newborn has not been established. Clearly the management of vivax malaria in pregnancy must be improved.

### Acknowledgments

We would like to thank all patients and staff of SMRU for their contribution.

### Author Contributions

Conceived and designed the experiments: MEB MJR SP NJW RMG FHN. Performed the experiments: MEB MJR APP MP RMG. Analyzed the data: MEB MJR FHN. Contributed reagents/materials/analysis tools: TL NLK SP NL MI. Wrote the paper: APP SP NL MI PS NJW FHN MEB MJR TL RMG.

### References

1. Wickramasuriya GAW (1936) Malaria and ankylostomiasis in the pregnant woman, their more serious complications and sequelae.

2. Diagne N, Rogier C, Sokhna CS, Tall A, Fontenelle D, et al. (2000) Increased susceptibility to malaria during the early postpartum period. N Engl J Med 343: 598–603.

3. Ramharter M, Grobusch MP, Kieslings G, Adegnika AA, Moller U, et al. (2005) Clinical and parasitological characteristics of puerperal malaria. J Infect Dis 191: 1005–1009.

4. Bottero J, Briand V, Agbowai C, Doritchamou J, Massougbodji A, et al. (2011) Spontaneous postpartum clearance of Plasmodium falciparum parasitemia in pregnant women, Benin. Am J Trop Med Hyg 84: 267–269.

5. Nguyen-Dinh P, Steker RW, Greenberg AE, Wirima JJ, Mulenda O, et al. (1998) Rapid spontaneous postpartum clearance of Plasmodium falciparum parasitaemia in African women. Lancet 2: 751–752.

6. Boel ME, Rijken MJ, Brabin BJ, Nosten F, McGready R (2012) The epidemiology of postpartum malaria: a systematic review. Malar J 11: 114.

7. Serra-Cassas E, Menezes C, Dobano C, Bardaji A, Quinto L, et al. (2011) Persistence of Plasmodium falciparum parasites in infected pregnant Mozambican women after delivery. Infect Immun 79: 298–304.

8. Nosten F, ter Kuile FO, Agyare VE, Auma L, Dechuff B, White NJ (1999) Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 85: 424–429.

9. Carrara VI, Sirilak S, Thonglairmin J, Rojanawatvisitvech P, Proux S, et al. (2006) Deployment of early diagnosis and melquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLos Med 3: e185.

10. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, et al. (2000) Deployment of early diagnosis and mefloquine-artesunate treatment of Plasmodium falciparum malaria in Thailand. Trans R Soc Trop Med Hyg 85: 424–429.

11. Ronda HE, Sanders RM, Van den Ende J, Scott SM, Wernsdorfer WH, et al. (2000) Distribution of msp1 and msp2 allelic variants in Plasmodium falciparum in Africa. Trends Parasitol 16: 350–354.

12. WHO (2010) Guidelines for the treatment of malaria: WHO. Geneva: World Health Organization.

13. Therneau T, Grambsch P, Pankratz V (2003) Penalized survival models and frailty. J Computational and Graphical Statistics 12: 156–173.

14. Snounou G (2002) Genotyping of Plasmodium spp. Nested PCR. Methods Mol Med 72: 103–116.

15. Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L, et al. (1999) Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 60: 41–48.

16. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, et al. (1999) Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93: 369–374.

17. Villegas L, McGready R, Hwaw M, Paw MK, Pimanpanarak M, et al. (2007) Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health 12: 209–216.

18. Thane T, Grambsch P, Pankraz V (2005) Penalized survival models and frailty. J Computational and Graphical Statistics 12: 156–173.

19. Luxemburger C, Thwaites KL, White NJ, Webster HK, Kyle RE, et al. (1996) The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 90: 105–111.

20. Rothman KJ (2007) Modern Epidemiology, 3rd edition.

21. Imwong M, Boel ME, Pagornrat W, Pimanpanarak M, McGready R, et al. (2011) The First Plasmodium vivax Relapses of Life Are Usually Genetically Homologous. J Infect Dis 205: 680–683.

22. Imwong M, Snounou G, Pukrittayakamee S, Tansomsing N, Kim JR, et al. (2007) Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 937–939.

23. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, et al. (2011) Dihydroartemisinin-piperquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 53: 977–984.

24. White NJ (2010) Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297.

25. Pradines B, Rogier C, Fusi A, Tall A, Trape JF, et al. (1998) In vitro activity of artemether against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. Am J Trop Med Hyg 58: 354–357.

26. Pradines B, Tall A, Parzy D, Spiegel A, Fusi T, et al. (1998) In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J Antimicrob Chemother 42: 335–339.

27. Bottius E, Guanzirolli A, Trape JF, Rogier C, Konate L, et al. (1996) Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction. Trans R Soc Trop Med Hyg 90: 15–19.

28. Dolan G, ter Kuile FO, Jacoutot V, White NJ, Luxemburger C, et al. (1993) Bed nets for the prevention of malaria and anaemia in pregnancy. Trans R Soc Trop Med Hyg 87: 620–626.